stockrowDisc Medicine, Inc.
IRON Healthcare Biotechnology
- EPS
- +2.53%
- Free cash flow
- +7.83%
- Total debt
- +106.5%
Quarter to June 2026, against a year earlier
Follow IRON
Alert me
Disc Medicine, Inc. (IRON) Return on equity
Disc Medicine, Inc.'s return on equity over the twelve months to 30 June 2026 was −39.1%, down 3.2 percentage points from fiscal 2025 (−35.9%). Over the past ten years it has ranged from −83.3% (fiscal 2022) to 186.8% (fiscal 2020); the current reading is higher than 22% of that period. That is above the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −35.9% | (8.13) |
| FY2024 | −27.7% | 1.57 |
| FY2023 | −29.3% | 54.02 |
| FY2022 | −83.3% | (83.32) |
| FY2022 | 0.00% | (83.59) |
| FY2021 | 83.6% | 83.59 |
| FY2021 | 0.00% | (186.80) |
| FY2020 | 186.8% | 186.80 |
| FY2020 | 0.00% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 31.4% |
| PBLS Parabilis Medicines, Inc. compare | 0.00% |
| TNGX Tango Therapeutics, Inc. compare | −21.3% |
| IOVA Iovance Biotherapeutics, Inc. compare | −29.1% |
| RLAY Relay Therapeutics, Inc. compare | −36.8% |
| IRON Disc Medicine, Inc. | −39.1% |
| XENE Xenon Pharmaceuticals Inc. compare | −43.6% |
| DYN Dyne Therapeutics, Inc. compare | −81.6% |
| VKTX Viking Therapeutics, Inc. compare | −96.4% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)